Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Prozorovski T, Meier S, Osman-ova V, Kwidzinski E, Pohl E, Beyer M, Bechmann I, Nitsch R, Zipp F (2005) Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46:421-432

Adams R (1941) Marihuana. Harvey Lect 37:168

Alger BE (2002) Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68:247-286

Arevalo-Martin A et al. (2003) Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23:2511-2516 Azad SC et al. (2003) Activation of the cannabinoid receptor type 1 decreases glutamater-gic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 10:116-128

Baker D et al. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-87 Baker D et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300-302

Baker D, Pryce G (2004) The potential role of the endocannabinoid system in the control of multiple sclerosis. Curr Med Chem 4:195-202 Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7:111-118

Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Perkin GD, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123(Pt 11):2321-2337 Bátkai S et al. (2001) Endocannabinoids acting at vascular CBi receptors mediate the vasodilated state in advanced liver cirrhosis. Nature Med 7:827-832 Beltramo M et al. (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097 Beltramo M et al. (2000) Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor. J Neurosci 20:3401-3407 Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V (1997) Influence of fatty acid ethanolamides and delta-9-tetrahydrocannabinol on cytokine and arachido-nate release by mononuclear cells. Eur J Pharmacol 330:231-240 Beuckmann CT et al. (2000) Cellular localization of lipocalin-type prostaglandin D synthase (^-trace) in the central nervous system of the adult rat. J Comp Neurol 428:62-78 Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: consequences for understanding the pro gressive phase of the disease. J Neurol Sci 206:165-171 Bojensen IN, Hansen HS (2003) Binding of anandamide to bovine serum albumin. J Lipid Res 44:1790-1794

Bouaboula M, Bourrie B, Rinaldi-Carmona M, Shire D, Le Fur G, Casellas P (1995) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 270:13973-13980 Bouaboula M, Poinot Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi Carmona M, Le Fur G, Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641 Bouaboula M, Poinot Chazel C, Marchand J, Canat X, Bourrie B, Rinaldi Carmona M, Calandra B, Le Fur G, Casellas P (1996) Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237:704-711 Brady CM et al. (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10:425-433 Carlson G, Wang Y, Alger BE (2002) Endocannabinoids facilitate the induction of LTP in the hippocampus. Nature Neurosci 5:723-724

Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, Pfister SL, Campbell WB, Hillard CJ (2004) Cultured rat microglial cells synthesize the endo-cannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65:999-1007 CaulfieldMP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231-232

Chapman KD (2002) Emerging physiological roles for N-acylphosphatidylethanolamine metabolism in plants: signal transduction and membrane protection. Chem Phys Lipids 108:221-229

Christison R (1848) In: Lea, Blanchard (eds) A Dispensatory, or Commentary on the

Pharmacopoeias of Great Britain (and the United States), Philadelphia:971-974 Coles AJ et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296-304 Correa F, Mestre L, Molina-Holgado E, Arevalo-Martin A, Docagne F, Romero E, Molina-Holgado F, Borrell J, Guaza C (2005) The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. Mini Rev Med Chem 5:671-675

CravattBF et al. (1996) Molecular characterization of an enzyme that degrades neuro-

modulatory fatty-acid amides. Nature 384:83-87 Croxford JL, Yamamura T (2005) Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166:3-18 Danton GH, Dietrich WD (2003) Inflammatory mechanisms after ischemia and stroke.

J Neuropathol Exp Neurol 62:127-136 De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52-56

Derkinderen P, Toutant M, Burgaya F, Le Bert M, Siciliano JC, de Franciscis V, Gelman M, GiraultJA (1996) Regulation of a neuronal form of focal adhesion kinase by anan-damide. Science 273:1719-1722 Derkinderen P, Valjent E, ToutantM, Corvol JC, Enslen H, Ledent C, Trzaskos J, Caboche J, Girault JA (2003) Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23:2371-2382 Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949 Devane WA, Dysarz FA, Johnson MR, Melvin LS, HowlettAC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613 Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691 Dinh TP et al. (2002) Brain monoglyceride lipase participating in endocannabinoid inac-

tivation. Proc Natl Acad Sci USA 99:10819-10824 Dirnagl U, Iadecola C, MoskowitzMA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22(9):391-397 Drew PD, Chavis JA (2000) Inhibition of microglial cell activation by cortisol. Brain Res Bull 52:91-396

Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O (2003) Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 100(23):13632-13637

Eljaschewitsch E, Witting A, Mawrin C, Lee T, Schmidt PM, Wolf S, Hoertnagl H, Raine CS, Schneider-Stock R, Nitsch R, Ullrich O (2006) The endocannabinoid anandamide (AEA) protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron (in press) Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A (2003) Cannabinoids ablate release of TNFa in rat microglial cells stimulated withlypopolysaccharide. Glia 41:161168

Farooqui AA, Rammohan KW, Horrocks LA (1989) Isolation, characterization, and regulation of diacylglycerol lipases from the bovine brain. Ann NY Acad Sci 559:25-36 Ferguson B et al. (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393399

Filippi M et al. (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126:433-437 Floden AM, Li S, Combs CK (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25(10):2566-2575 Floyd RA (1999) Neuroinflammatory processes are important in neurodegenerative diseases: an hypothesis to explain the increased formation of reactive oxygen and nitrogen species as major factors involved in neurodegenerative disease development. Free Radic Biol Med 26:1346-1355 FlugelA, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z, EllwartJW, Willem M, Lassmann H, Wekerle H (2001) Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14(5):547-560 FranklinA, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N (2003) Palmitoyl-ethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 23:7767-7775 Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabi-noid receptors in human immune tissue and leukocyte subpopulations. Eur J Biochem 232:54-61

Gallily R, Breuer A, Mechoulam R (2000) 2-Arachidonylglycerol, an endogenous cannabi-noid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406:5-7 Galve-Roperh I, Sanchez C, Cortes L, del Pulgar TG, Izquierdo M, Guzman M (2000) Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal regulated kinase activation. Nat Med 6:313-319 Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647 Garden GA (2002) Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 40:240-251 Gebicke-Haertner PJ, van Calker D, Norenberg W, Illes P (1996) Molecular mechanisms of microglial activation. Implications for regeneration and neurodegenerative diseases. Neurochem Int 29:1-12 Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471 Gessa GL, Casu MA, Carta G, Mascia MS (1998) Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 355:119-124

Gifford AN, Ashby CR Jr (1996) Electrically evoked acetlycholine release from hippocam-pal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 277:1431-1436

Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ (2005) A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 37(5):526-531 Giuffrida A, Parsone LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Pomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363

Giulian D, Haverkamp LJ, Yu JH, Karshin W, Tom D, Li J et al. (1996) Specific domains of beta-amyloid from Alzheimer's plaque elicit neuron killing in human microglia. J Neurosci 1996:6021-6037 Gomez del Pulgar T, Velasco G, Guzman M (2000) The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347:369-373 Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5(1):69-81

GorritiMA, Rodriguez de Fonseca F, Navarro M, Palomo T (1999) Chronic (-)-A9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365:133-142 Graeber MB, Scheithauer BW, Kreutzberg GW (2002) Microglia in brain tumors. Glia 40:252-259

Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin

Pharmacokinet 42:327-360 Guzman M, Sanchez C, Galve-Roperh I (2001) Control of the cell survival/death decision by cannabinoids. J Mol Med 78:613-625 Hampson AJ et al. (2000) Neuroprotective antioxidants from marijuana. Ann New York

Acad Sci 899:274-282 Hanisch UK (2002) Microglia as a source and target of cytokines. Glia 40(2):140-155 Hanisch UK, Lyons S, Nolte C, Prinz M, Weber J, Kettenmann H, Kirchhoff F (1997) Mouse brain microglia express interleukin-15 and its multimeric receptor complex functionally coupled to Janus kinase activity. J Biol Chem 272:28853-28860 Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikono-midou C, Schmid HHO, Fernandez-Ruiz JJ, Hansen HS (2001) Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 78:1415-1427

Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665 Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Ban-ion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128(Pt 6):1442-1453 Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH (2004) Presence of dendritic cells, MCP-1, and activated mi-croglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55:221-235

Heppner F, Skutella T, Hailer NP, Haas D, Nitsch R (1998) Activated microglial cells migrate towards site of excitotoxic neuronal injury inside organotypic hippocampal slice cultures. Eur J Neurosci 10:3284-3290

Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990)

Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936 Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267-274 Hernandez-Lopez S et al. (2000) D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC1-IP3-calcineurin-signaling cascade. J Neurosci 20:8987-8995 Higgs HN, Glomset JA (1994) Identification of a phosphatidic acid-preferring phospholi-

pase A1 from bovine brain and testis. Proc Natl Acad Sci USA 91:9574-9578 Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB (1995) Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1257:249-256 Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69:631-638 HoekRM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, HomolaME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD (2000) Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290(5497): 1768-1771

Hoffman AF, Lupica CR (2000) Mechanisms of cannabinoid inhibition of GABAa synaptic transmission in the hippocampus. J Neurosci 20:2470-2479 Hohmann AG, Herkenham M (1999) Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 92:1171-1175 Hohmann AG, Herkenham M (2000) Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37:71-80

HowlettAC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci 35:1803-1813 Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731-748 Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, PetrosTJ, KreyJF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, DiMarzoV (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400-8405 Huestis MA et al. (1992) Blood cannabinoids; I. absorption of THC and formation of 11-OH-THC and THC-COOH during and after smoking marijuana. J Anal Toxicol 16:228-235

Iversen L, Chapman V (2002) Cannabinoids: a real prospect for pain relief. Curr Opin Pharmacol 2:50-55

Jacobsson SO, Rongard E, Stridh M, Tiger G, Fowler CJ (2000) Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 60:1807-1813

Jennings EA, Vaughan CW, Christie MJ (2001) Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J Physiol 534:805-812 Kaminski NE (1998) Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol 83:124-132 Kathuria S et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med 9:76-81

Katona I et al. (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:45444558

Katona I et al. (2001) Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci 21:9506-9518 Killestein J et al. (2002) Safety, tolerability and efficacy of orally administered cannabi-

noids in MS. Neurology 58:1404-1407 Kim J, Isokawa M, Ledent C, Alger BE (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 22:10182-10191

Klegeris A, Bissonnette CJ, McGeer PL (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharamacol 139:775-786 Kodaki T, Yamashita S (1997) Cloning, expression, and characterization of a novel phos-

pholipase D complementary DNA from rat brain. J Biol Chem 272:11408-11413 Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, Levison SW (2005) Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 54(5):1559-1565

Kreitzer AC, Regehr WG (2001) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 21:RC174 Kreutzberg GW (1996) Microglia. A sensor for pathological events in the CNS. TINS 19(8):312-318

Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaquaeductal gray involvement. J Pharmacol Exp Ther 276:585-593 Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyanis A, Kunos G (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346:835-840

Llano I, Leresche N, Marty A (1991) Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron 6:565-574

Lockhart BP, CresseyKC, Lepagnol JM (1998) Supression of nitric oxide formation by tyrosine kinase inhibitors in murine N9 microglia. Br J Pharmacol 123:879-889 Lopez-Rodriguez ML et al. (2001) Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem 44:4505-4508 Maccarrone M, Lorenzon T, Bari M et al. (2000) Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275:31938-31945 Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuro-

blastoma-glioma cells. Proc Natl Acad Sci USA 89:3825-3829 Marsicano G, Lutz B (1999) Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225 Marsicano G et al. (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534 Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cas-cio MG, Gutiérrez SO, van der Stelt M, López-Rodríguez ML, Casanova E, Schütz G, Zieglgänsberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. Science 302:84-88

Martin WJ et al. (1999) Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res 822:237-242 Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002) Involvement of CB1

cannabinoid receptors in emotional behaviour. Psychopharmacology 159:379-387 Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564 Matyszak MK, Denis-Donini S, Citterio S, Longhi R, Granucci F, Ricciardi-Castagnoli P (1999) Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur J Immunol 29(10):3063-3076 McDonald AJ, Mascagni F (2001) Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 107:641-652 McGeer PL, McGeer EG (2000) Autotoxicity and Alzheimer disease. Arch Neurol 57(6):789-790

McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neuro-

biology of Aging 22:799-809 McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12(Suppl 2):S1-S6

McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21:195-218

Mechoulam R et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90 Mechoulam R, Lichtman AH (2003) Stout Guards of the Central Nervous System. Science 302:65-67

Meng ID, Manning BH, Martin WJ, Field HL (1998) An analgesia circuit activated by cannabinoids. Nature 395:381-383 Meyer R, Weissert R, Diem R, Storck MK, de Graaf KL, Kramer B, Bähr M (2001) Acute

Neuronal Apoptosis in a Rat Model of Multiple Sclerosis. J Neurosci 21:6214-6220 Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 5(1):49-55 Monje ML, Toda H, Palmer TD (2003) Inflammatory blockade restores adult hippocampal neurogenesis. Science 302(5651):1760-1765 Moreau JJ (1845) Du Hachisch et de l'Aliénation Mentale. Fortin, Masson & Co., Paris Mu J, Zhuang SY, KirbyMT, Hampson RE, DeadwylerSA (1999) Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther 291:893-902 Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003) A9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459-465 Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65 Nau R, Bruck W (2002) Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trend Neurosci 25:38-45 Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496 Neumann H (2001) Control of glial immune function by neurons. Glia 36(2):191-199

Nimmerjahn A, KirchhoffF, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726):1314-1318 Ohlsson A et al. (1980) Plasma delta-9 tetrahydrcannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409-416

Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M (2002) Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci 22:3864-3872 van Oosten BW et al. (2004) Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist. Mult Scler 10:330-331 O'Shaugnessy WB (1843) On the Cannabis indica or Indian hemp. Pharmacol J Trans 2:594 Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531

Pertwee RG (2000) Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp Opin Invest Drugs 9:1-19

Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmacol Ther 95:165-174 Pete MJ, Ross AH, Exton JH (1994) Purification and properties of phospholipase A1 from bovine brain. J Biol Chem 269:19494-19500 PetrovaTV, Akama KT, Van Eldik LJ (1999) Selective modulation of BV-2 microglial activation by prostaglandin E(2). Differential effects on endotoxin-stimulated cytokine induction. J Biol Chem 274:28823-28827 Piomelli D et al. (1999) Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci USA 96:5802-5807 Piomelli D (2001) The ligand that came from within. Trends Pharamcol Sci 22:17-19 Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884

Piomelli D, Greengard P (1990) Lipoxygenase metabolites of arachidonic acid in neuronal transmembrane signalling. Trend Pharmacol Sci 11:367-373 Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45-60 Porter AC et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020-1024 Pryce G et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126:2191-2202 Romero J et al. (2002) The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 95:137-152 Rueda D, Galve-Roperh I, Haro A, Guzman M (2000) The CB1 cannabinoid receptor is coupled to the action of c-Jun N-terminal kinase. Mol Pharmacol 58:814-820 Rouyer M (1810) Sur les medicaments usuels des Egyptiens. Bull Pharmacie 2:25 Sailer M et al. (2003) Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126:1734-1744

Sanchez C, deCeballos ML, DelPulgarTG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, Guzman M (2001) Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61:5784-5789

Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M (1998) A9-tetrahydrocanna-binoid induces apoptosis in C6 glioma cells. FEBS Lett 436:6-10

Sanchez C, Galve-Roperh I, Rueda D, Guzman M (1998) Involvement of shingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the A9-tetrahydro-cannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54:834-843

Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP, DiFigliaM (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 60(2):161-72 Sarker KP, Obara S, Nakata M, Kitajima I, Maruyama I (2000) Anandamide induces apop-

tosis of PC-12 cells: involvement of superoxide and caspase-3. FEBS Lett 472:34-44 Schlicker E, Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharamcol Sci 22:565-572 Schmid PC, Zuzarte-Augustin ML, Schmid HH (1985) Properties of rat liver N-acyl-

ethanolamine amidohydrolase. J Biol Chem 260:14145-14149 Schwartz M, Kipnis J (2005) Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 233(1-2):163-166 Shakespeare DT et al. (2003) Anti-spasticity agents for multiple sclerosis. Cochrane

Database Syst Rev 4:CD001332 SieradzanKA, Fox SH, Hill M, DickJP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108-2111

Song ZH, Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol 49:891896

Stefano GB, Liu Y, GoligorskyMS (1996) Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem 271:19238-19242 Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773-778 Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol 425:189-196 Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K(1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97 Svendsen KB et al. (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J 329:253

Szolcsanyi J (2000) Anandamide and the question of its functional role for activation of capsaicin receptors. Trend Pharmacol Sci 21:203-204 Takeda H, Tomita M, Tanahashi N, Kobari M, Yokoyama M, Takao M, Ito D, Fukuuchi Y (1998) Hydrogen peroxide enhances phagocytic activity of amoeboid microglia. Neu-rosci Lett 240:5-8

Timpone JC et al. (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 13:305-315 Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411

Trapp BD et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285

Turner MR, Cagnin A, Turkheimer FE, Miller CC, ShawCE, Brooks DJ, Leigh PN, Ba-nati RB (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15:601-609

TwitchellW, Brown S, Mackie K (1997) Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78:43-50 Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T (1995) Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 270:23823-23827 Ulvestad E, Williams K, BjerkvigR, Tiekotter K, Antel J, Matre R (1994) Human mi-croglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc Biol 56(6):732-740 Vaney C et al. (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:417-424 Varma N, Carlson GC, Ledent C, Alger BE (2001) Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci 21:RC188 Versijpt J, Debruyne JC, Van Laere KJ, De Vos F, Keppens J, Strijckmans K, Achten E, Slegers G, DierckxRA, KorfJ, DeReuckJL (2005) Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 11(2):127-134 Wade DT et al. (2004) Do cannabis based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434-441 Waksman Y, Olson JM, Carlisle SJ, Cabral GA (1999) The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288:1357-1366 Wall ME et al. (1983) Metabolism, disposition and kinetics of delta-9-tetrahydrocanna-

binol, in men and women. Clin Pharmacol Ther 34:352-363 Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96:12198-12203

Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N (2003) Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405

Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141:775785

Wartmann M, Campbell D, Subramanian A, Burstein SH, Davis RJ (1995) The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett 359:133-136 Wilson RI, Kunos G, Nicoll RA (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31:1-20 Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592 Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678-682 Xie XQ, Melvin LS, Makriyannis A (1996) The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. J Biol Chem 271:10640-10647 Zajicek J et al. (2003) Cannabinoids for the treatment of other symptoms related to multiple sclerosis (CAMS study): multicentre, randomized, placebo-controlled trial. Lancet 362:1517-1526

Zajicek J et al. (2004) The cannabinoids in MS study - final results from 12 months follow-up. Mult Scler 10:S115

Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19(6):533-542 Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457

Anxiety and Depression 101

Anxiety and Depression 101

Everything you ever wanted to know about. We have been discussing depression and anxiety and how different information that is out on the market only seems to target one particular cure for these two common conditions that seem to walk hand in hand.

Get My Free Ebook

Post a comment